Correspondence 0001575872-23-001269 from INSPIRE VETERINARY PARTNERS, INC. (IVPR)
INSPIRE VETERINARY PARTNERS, INC.
Date: Aug. 2, 2023 · CIK: 0001939365 · Accession: 0001575872-23-001269
AI Filing Summary & Sentiment
File numbers found in text: 333-271198
Referenced dates: July 31, 2021, July 31, 2023
Show Raw Text
CORRESP
1
filename1.htm
VIA
EDGAR
August
2, 2023
THE
UNITED STATES SECURITIES
AND
EXCHANGE COMMISSION
Office
of Industrial Applications and Services
Division
of Corporation Finance
Washington,
D.C. 20549
Attn:
J. Conlon Danberg
Re:
Re:
Inspire Veterinary Partners, Inc.
Amendment
No. 4 to Registration Statement on Form S-1
Filed
July 17, 2023
File
No. 333-271198
Dear
Mr. Danberg:
We
write on behalf of Inspire Veterinary Partners, Inc. (the “Company”) in response to comments by the United States Securities
and Exchange Commission (the “Commission”) in its letter dated July 31, 2023, commenting on the Company’s Amended Registration
Statement on Form S-1 filed July 17, 2023 (the “Registration Statement”). This correspondence addresses Comments No. 1, 3,
4, and 5 in the Commission’s letter dated July 31, 2021. The Company’s response to Comment No. 2 in the staff’s letter
of July 31 has been addressed in previously-filed correspondence addressed to Nudrat Salik and Terrence O’Brien.
Titling
and paragraph numbering of the comment below corresponds to the titling and numbering used in the Commission’s comment letter.
Amendment
No. 4 to Form S-1
Risk
Factors
Our
board of directors may designate. . ., page 23
1.
We refer to your revised statement that you anticipate Mr. Keiser will own 48.5% of the voting power and an economic interest in approximately
34.7% of your outstanding common stock immediately following the closing of the offering. We also note your revised statement that Mr.
Keiser and certain other directors and affiliate will control a combined 39.3% of the voting power and an economic interest in approximately
28.9% of your outstanding common stock. Please revise, as this information does not appear to be consistent, and does not appear to be
consistent with the information in the beneficial ownership table.
United States Securities and Exchange Commission
Attn: J. Conlon Danberg
August 2, 2023
Page 2 of 3
Response:
In response to this comment, the Company has amended the figures in this risk factor to correct and update them and render them consistent
with disclosures in the beneficial ownership table.
Use
of Proceeds, page 32
3.
We note that you have filed a free writing prospectus on July 27, 2023 indicating that you have entered into letters of intent for three
new locations. Please revise to identify the businesses and the status of your negotiations with respect to these acquisitions. Refer
to Item 504 of Regulation S-K.
Response:
In response to this comment, the Company has amended the use of proceeds disclosure in the Registration Statement to identify the three
businesses under consideration and to indicate the current status of negotiations with these businesses. Specifically, the additional
disclosure explains that no binding agreements to acquire these or any other specific businesses have been executed. The Company has
begun preliminary due diligence activities with regard to these potential acquisitions and can provide no assurance that any or all of
such acquisitions will in fact occur.
Security
Ownership of Certain Beneficial Owners and Management, page 76
4.
We acknowledge your revised disclosures. Please also revise the narrative lead-in to the table to explain the number of shares outstanding
that you are using, with respect to each of the following scenarios: before the offerings, after the primary offering, and after the
secondary offering.
Response:
In response to this comment, the Company has amended this portion of the Registration Statement to include introductory information before
the beneficial ownership table which explains the number of shares used in the calculations for each of the columns in the table.
General
5.
We note that your amended and restated bylaws that you have filed includes an exclusive forum provision. Please revise your prospectus
to clearly and prominently describe this provision, including the forum for litigation. In addition, please add a risk factor to describe
the risks of such a provision, including that there may be increased costs for stockholders to bring a claim and that the provision can
discourage or limit investors' ability to bring a claim in a judicial forum that they find favorable. Please also disclose whether this
provision applies to actions arising under the Securities Act or Exchange Act. If this provision does not apply to actions arising under
the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly,
or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities
Act or Exchange Act.
Response:
In response to this comment, the Company has amended its bylaws to strike the exclusive forum provision. Amended bylaws for the Company
have been filed as new Exhibit 3.3 to the Registration Statement.
United States Securities and Exchange Commission
Attn: J. Conlon Danberg
August 2, 2023
Page 3 of 3
Please
feel free to contact me should you require additional information at (775) 234-5221 or jlaxague@cronelawgroup.com.
THE CRONE LAW GROUP, P.C.
By:
/s/ Joe Laxague
Joe Laxague, Esq.